Early monitoring of external radiation therapy by [18F]-fluoromethylcholine positron emission tomography and 3-T proton magnetic resonance spectroscopy: An experimental study in a rodent rhabdomyosarcoma model

Nuclear Medicine and Biology

Volumn 37, Issue 5, 2010, Pages 645-653

  Rommel, Denis ^a   Abarca Quinones, Jorge ^a   Bol, Anne ^a   Peeters, Frank ^a   Lhommel, Renaud ^a   Lonneux, Max ^a   Labar, Daniel ^a   Gregoire, Vincent ^a   Duprez, Thierry ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

H MRS; Irradiation; PET; Rodent; Therapeutic monitoring

Indexed keywords

FLUOROMETHYLCHOLINE F 18; TRACER; UNCLASSIFIED DRUG; ALGINIC ACID; CHOLINE; FLUOROMETHYLCHOLINE; GLUCURONIC ACID; HEXURONIC ACID; PROTON;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; IRRADIATION; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION DOSE; RAT; RHABDOMYOSARCOMA; ANALOGS AND DERIVATIVES; ANIMAL; DIAGNOSTIC USE; DISEASE MODEL; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROCEDURES; SCINTISCANNING; SURVIVAL RATE; TIME; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

ALGINATES; ANIMALS; BIOLOGICAL TRANSPORT; CHOLINE; DISEASE MODELS, ANIMAL; GLUCURONIC ACID; HEXURONIC ACIDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTONS; RATS; RHABDOMYOSARCOMA; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953810110     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.03.005     Document Type: Article

References (38)

1. Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev Cancer 2008, 8:94-107.
2. Artemov D., Bhujwalla Z., Bulte J. Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr Pharm Biotechnol 2004, 5:485-494.
3. Leach M., Brindle K., Evelhoch J., et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005, 92:1599-1610.
4. McDonald D., Choyke P. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003, 9:713-725.
5. Meisamy S., Bolan P., Baker E., et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy-a pilot study at 4 T. Radiology 2004, 233:424-431.
6. Kurhanewicz J., Vigneron D., Nelson S. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2000, 2:166-189.
7. Chen C., Li C., Kuo Y., et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants-initial experience. Radiology 2006, 239:448-456.
8. Glunde K., Jacobs M., Bhujwalla Z. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn 2006, 6:821-829.
9. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999, 12:413-439.
10. Kwee S., Coel M., Lim J., Ko J. Combined use of F-18 fluorocholine positron emission tomography and magnetic resonance spectroscopy for brain tumor evaluation. J Neuroimaging 2004, 14:285-289.
11. 3H]choline uptake in the human prostate cancer cell lines LNCaP and PC3. Strahlenther Onkol 2008, 184:319-324.
12. Animal Welfare AVMA policy - Use of Animals in Research, Testing, and Education (2007) AVMA Website available via:, [Accessed 28 Nov 2009]. http://www.avma.org/issues/policy/animal_welfare/testing.asp.
13. Rommel D., Abarca-Quinones J., Christian N., et al. Alginate moulding: an empirical method for magnetic resonance imaging/positron emission tomography co-registration in a tumor rat model. Nucl Med Biol 2008, 35:571-577.
14. MRUI Versions (2006) Available via:, [Accessed 28 Nov 2009]. http://sermn02.uab.cat/mrui/mrui_Overview.shtml.
15. 1H spectroscopic imaging data sets. NMR Biomed 1992, 5:171-178.
16. van den Boogaart A., van Ormondt D., Pijnappel W.W.F., de Beer R., Ala-Korpela M. HLSVD water filtering. Mathematics in signal processing III 1994, 175-195. Clarendon Press, Oxford. J.G. McWhirter (Ed.).
17. 18F]fluorocholine. Appl Radiat Isot 2002, 5:347-352.
18. 11C]methyl triflate. Appl Radiat Isot 2001, 55:17-22.
19. Huisman M.C., Reder S., Weber A.W., Ziegler S.I., Schwaiger M. Performance evaluation of the Philips MOSAIC small animal PET scanner. Eur J Nucl Med Mol Imaging 2007, 34:532-540.
20. Perini R., Choe R., Yodh A., Sehgal C., Divgi C., Rosen M. Non-invasive assessment of tumor neovasculature: techniques and clinical applications. Cancer Metastasis Rev 2008, 27:615-630.
21. Michaelis L., Ratain M. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006, 6:409-414.
22. Seierstad T., Røe K., Olsen D. Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model. Radiother Oncol 2007, 85:187-194.
23. 1H spectroscopic imaging. Clin Cancer Res 2003, 9:4529-4536.
24. Buerkle A., Weber W. Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev 2008, 27:545-554.
25. Takahashi N., Inoue T., Lee J., Yamaguchi T., Shizukuishi K. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology 2007, 72:226-233.
26. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001, 61:110-117.
27. Rosenbaum S., Lind T., Antoch G., Bockisch A. False-positive FDG PET uptake-the role of PET/CT. Eur Radiol 2006, 16:1054-1065.
28. 18F]FDG PET in clinical oncology. Lancet Oncol 2007, 8:822-830.
29. Zeisel S.H. Choline: essential for brain development and function. Adv Pediatr 1997, 44:263-295.
30. Iorio E., Mezzanzanica D., Alberti P., et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 2005, 65:9369-9376.
31. Villa A., Caporizzo E., Papagni A., et al. Choline and phosphatidylcholine fluorescent derivatives localization in carcinoma cells studied by laser scanning confocal fluorescence microscopy. Eur J Cancer 2005, 41:1453-1459.
32. Michel V., Yuan Z., Ramsubir S., Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med 2006, 231:490-504.
33. Eliyahu G., Kreizman T., Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer 2007, 120:1721-1730.
34. Hara T., Bansal A., DeGrado T. Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 2006, 5:498-509.
35. 18F-Choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging 2004, 31:312-316.
36. Milosevic M., Fyles A., Hill R. The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int J Radiat Oncol Biol Phys 1999, 43:1111-1123.
37. Rosi A., Grande S., Luciani A.M., et al. (1H) MRS studies of signals from mobile lipids and from lipid metabolites: comparison of the behavior in cultured tumor cells and in spheroids. NMR Biomed 2004, 17:76-91.
38. Monazzam A., Josephsson R., Blomqvist C., Carlsson J., Långström B., Bergström M. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer. Breast Cancer Res 2007, 9:R45.